2025年 Immuno-Oncology Summitにおける主要ファーマ・革新的バイオテクノロジーによるプレゼンテーション

業界のパイオニア、ソートリーダー、インフルエンサーによるプレゼンテーションでは、がん免疫における最新のブレイクスルーをご紹介します。

---

Engineering Antibody-Drug Conjugates for Optimal Payload Delivery in Solid Tumors
Ian Nessler, PhD, Senior Scientist II, Quantitative, Translational, and ADME Sciences, AbbVie

Functional Effects of Cancer Cell Phagocytosis on Tumor Macrophages
Kristin V. Tarbell, PhD, Associate Director, Discovery, Amgen

Women in Science Meet-Up
Amina Metidji, PhD, Senior Scientist, AstraZeneca

Advancing Drug Discovery with Hypoxic 3D Tumor Models
Orna Rabinovich Ernst, PhD, Senior Scientist, R&D, AstraZeneca

Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T Cell Exclusion in Human Lung Tumors
Shilpa Keerthivasan, PhD, Associate Director, Immunology, Bristol Myers Squibb

Comparison of Cancer-Targeting and Stromal-Targeting Antibody-Drug Conjugates Using Bystander Quantitative Systems Pharmacology Models
Ezgi Wood, PhD, Associate Director, QSP, Bristol Myers Squibb

Impacts of ADCs on the Immune Response to Cancer
Ryan A. Heiser, PhD, Director Immuno-Oncology, Pfizer

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。